Group 1 - The core point of the article is that Juneng Co., Ltd. (stock code: 920578) is expected to report a net loss of between 170,000 to 260,000 yuan for the year 2025, indicating an increase in losses compared to the previous year [1][3] - The decline in net profit is primarily attributed to the macro market environment, with a slowdown in downstream customer investments leading to a year-on-year decrease in operating revenue [1][3] - Despite efforts to improve profitability through project structure optimization, margin enhancement, cost reduction, and better management of accounts receivable, the revenue decline has significantly impacted overall performance [1][3] Group 2 - On January 29, 2026, Juneng Co., Ltd. closed at 24.8 yuan, down 0.92%, with a turnover rate of 2.41%, a trading volume of 5,532 lots, and a transaction amount of 13.7694 million yuan [1] - On the same day, the net outflow of main funds was 25.14 thousand yuan, accounting for 1.83% of the total transaction amount, while speculative funds saw a net inflow of 37.1 thousand yuan, making up 2.69% of the total [1][3] - Retail investors experienced a net outflow of 62.66 thousand yuan, which represented 4.55% of the total transaction amount [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 股票代码：002391 股票简称：长青股份 公告编号：2026-007 江苏长青农化股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日至2025年12月31日。 2、业绩预告情况：预计净利润为正值且属于扭亏为盈 ■ 二、与会计师事务所沟通情况 三、业绩变动原因说明 2025年公司沿江厂区腾退搬迁改建项目产能得到有效释放，公司部分主导产品需求增长，带动公司综合 毛利率有所提升。 四、风险提示 本次业绩预告数据是公司财务部门初步测算的结果，具体财务数据以公司披露的2025年年度报告为准， 敬请广大投资者注意投资风险。 本次业绩预告未经过注册会计师预审计，但公司就本次业绩预告有关事项与会计师事务所进行了预沟 通，公司与会计师事务所在业绩预告方面不存在重大分歧，具体数据请以最终审计结果为准。 特此公告。 江苏长青农化股份有限公司董事会 2026年1月30日 ...

Core Viewpoint - The company, Shenzhen Guotian Group Co., Ltd., has announced a preliminary earnings forecast for the year 2025, indicating a loss but a significant narrowing of losses compared to the previous year [1][4]. Group 1: Earnings Forecast - The earnings forecast period is from January 1, 2025, to December 31, 2025 [1]. - The company anticipates a loss for the forecast period [2]. - The financial data related to this earnings forecast has not been audited by a registered accounting firm [3]. Group 2: Communication with Auditors - The company has communicated with its annual audit accounting firm regarding the earnings forecast, and there are no discrepancies between the company and the auditors on this matter [2]. Group 3: Reasons for Earnings Change - The company expects a steady recovery in business for 2025, benefiting from both cost-cutting and revenue-increasing measures, leading to a significant reduction in losses compared to the same period last year [4].

Group 1 - The company expects a decline in operating performance for the year 2025 compared to the previous year, primarily due to the termination of a business partnership with Peking University International Hospital, which will negatively impact revenue and net profit [2] - The company anticipates a non-recurring expense related to judicial arbitration, which is expected to reduce total profit by approximately 39 million to 45 million yuan [2] - Despite the challenges, the core generic drug business within the pharmaceutical industrial sector is expected to maintain healthy growth, with net profit projected to increase by around 30% compared to the same period last year [3] Group 2 - The company has communicated with its auditing firm regarding the performance forecast, and there are no disagreements between the company and the auditors concerning this forecast [1][2]

证券代码：688212 证券简称：澳华内镜 公告编号：2026-003 上海澳华内镜股份有限公司2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 经上海澳华内镜股份有限公司（以下简称"公司"）财务部门初步测算： 1、预计2025年度实现营业收入为76,431万元到77,439万元，与上年同期相比，将增加1,476.05万元到 2,484.05万元，同比上升1.97%到3.31%； 2、预计2025年度实现归属于母公司所有者的净利润为805万元到1,158万元，与上年同期相比，将减少 943.22万元到1,296.22万元，同比下降44.89%到61.69%； 3、本报告期，预计2025年度归属于母公司所有者的扣除非经常性损益后的净利润为-1,053万元到-700万 元。 （三）本次业绩预告相关财务数据未经注册会计师审计。 二、上年同期业绩情况和财务状况 2024年度公司实现营业收入74,954. ...

Core Viewpoint - Wuzhou Medical (301234) is expected to report a significant decline in net profit for the year 2025, with projections indicating a drop of 47.46% to 59.97% compared to the previous year [1][3] Trading Information Summary - On January 29, 2026, Wuzhou Medical closed at 40.38 yuan, down 0.54%, with a turnover rate of 1.05%, a trading volume of 7,143 lots, and a transaction amount of 28.97 million yuan [1] - On the same day, the net inflow of funds from major investors was 1.23 million yuan, while retail investors experienced a net outflow of 4.01 million yuan [1][3] Performance Disclosure Highlights - Wuzhou Medical has released a performance forecast for 2025, estimating a net profit attributable to shareholders of 16 million to 21 million yuan, which represents a year-on-year decline of 47.46% to 59.97% [1][3] - The company also anticipates a net profit of 11 million to 16 million yuan after deducting non-recurring gains and losses, reflecting a decrease of 54.98% to 69.05% year-on-year [1] - The decline in performance is attributed to reduced operating income, falling product prices, and increased exchange losses due to currency fluctuations [1]

Group 1 - The company expects a negative net profit for the fiscal year 2025, with the performance forecast period from January 1, 2025, to December 31, 2025 [1] - The company has communicated with its accounting firm regarding the performance forecast, and there are no disagreements between the company and the accounting firm on this matter [1][2] - The decline in revenue and gross margin is attributed to intensified competition in the ready-mixed concrete and municipal sanitation sectors [2] Group 2 - A total of 15,002,742 shares held by the shareholder Sanya Daxing Group Co., Ltd. are set to be auctioned, representing 1.31% of the company's total share capital [5][7] - The auction is a result of a debt dispute between Daxing Group and China Great Wall Asset Management Co., Ltd. Hainan Branch, and the shares are currently frozen [7] - The company’s daily operations will not be significantly impacted by this auction, and there will be no change in control of the company [5][8] Group 3 - The actual controller and their concerted actors hold a total of 321,444,590 shares, which is 28.01% of the total share capital [9] - If the auction is completed, the actual controller's shareholding will decrease to 306,441,848 shares, or 26.70% of the total, which could still significantly influence shareholder resolutions [9] - The actual controller faces risks related to pledged shares and potential judicial auction, which may affect the stability of control over the company [9]

Group 1 - The company expects a positive net profit for the year 2025, with an increase of over 50% compared to the previous year [2] - The performance improvement is attributed to strong demand in downstream industries and rising prices in the non-ferrous metal market, leading to increased sales volume and prices of the company's main products [3] - The company has made efficiency reforms that have resulted in cost reductions, contributing to revenue and operating profit growth year-on-year [3] Group 2 - The company plans to provide guarantees for its wholly-owned and controlling subsidiaries, with a total guarantee amount not exceeding 6.308 billion yuan [7] - Specific loan applications include 120 million yuan from Guangdong Shunbo Aluminum Alloy Co., Ltd. and 130 million yuan from Shunbo Alloy Anhui Co., Ltd. for working capital [8][9] - The company has a total guarantee balance of 3.393 billion yuan, which accounts for 106.61% of the company's latest audited net assets [15] Group 3 - The company received an administrative regulatory measure decision from the Chongqing Securities Regulatory Bureau due to issues related to income recognition and inventory impairment in 2024 [18][19] - The company is required to submit a written rectification report within 30 days, detailing corrective measures and establishing a long-term mechanism [19][21] - The regulatory measures will not affect the company's normal production and operations, and the company is committed to improving governance and information disclosure quality [21]

Group 1 - The company expects a positive net profit for the year 2025, with an increase of over 50% compared to the previous year [2] - The estimated net profit attributable to shareholders is projected to grow between 70.44% and 106.45% year-on-year, primarily due to the production of the Shantou photovoltaic project, increased grid prices for gas power projects, and a decrease in coal prices [4] - The net profit excluding non-recurring gains and losses is expected to change between -24.08% and 13.26% year-on-year, indicating that the growth rate of net profit attributable to shareholders is higher than that of net profit after excluding non-recurring items [4] Group 2 - The company has communicated with the accounting firm, but the performance forecast has not been audited by registered accountants [3] - The company has reported significant losses due to the impact of Typhoon "Hagupit" on its projects, which may lead to uncertainties in the performance forecast [5] - The financial data provided is preliminary and may differ from the final annual report data, which investors should be aware of [6]

最新公告列表 《2025年年度业绩预告公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年1月29日收盘，宏海科技（920108）报收于14.29元，较前一交易日下跌3.12%，最新总市值 为24.61亿元。该股当日开盘14.62元，最高14.76元，最低14.19元，成交额达2008.52万元，换手率为 3.94%。 宏海科技于2026年1月29日披露《2025年年度业绩预告公告》。公告显示，公司预计2025年度归属于上 市公司股东的净利润为1,300.00万元至1,700.00万元，较上年同期的6,544.24万元下降74.02%至80.14%。 业绩大幅下滑主要由于母公司受行业价格竞争及核心客户美的集团采购策略调整影响，营业收入减少； 子公司泰国宏海处于产能爬坡阶段，前期投入大，运营成本高，尚未形成显著收益；同时公司贷款规模 扩大导致利息费用增加，叠加汇率波动带来的汇兑损失，财务费用上升，对利润造成压力。本次业绩预 告为初步测算结果，未经审计，最终数据以年度报告为准。 ...